



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/140669/2020

European Medicines Agency decision P/0124/2020

of 24 March 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ladarixin (EMEA-002642-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0124/2020

of 24 March 2020

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ladarixin (EMA-002642-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Dompé farmaceutici SpA on 15 July 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ladarixin, age-appropriate oral liquid dosage form, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ladarixin, age-appropriate oral liquid dosage form, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for ladarixin, age-appropriate oral liquid dosage form, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Dompé farmaceutici SpA, Via Santa Lucia, 6, 20122 – Milano, Italy.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/691800/2019

Amsterdam, 28 February 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002642-PIP01-19

Scope of the application

Active substance(s):

Ladarixin

Condition(s):

Treatment of type 1 diabetes mellitus

Pharmaceutical form(s):

Age-appropriate oral liquid dosage form

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Dompé farmaceutici SpA

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Dompé farmaceutici SpA submitted for agreement to the European Medicines Agency on 15 July 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 August 2019.

Supplementary information was provided by the applicant on 29 November 2019. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of type 1 diabetes mellitus

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- age-appropriate oral liquid dosage form and capsule, hard; oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of type 1 diabetes mellitus

2.1.1. Indication(s) targeted by the PIP

Treatment of new-onset type 1 diabetes mellitus with residual beta cell function

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate oral liquid dosage form

Capsule, hard

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of a paediatric age-appropriate formulation (oral liquid) for use in children below 14 years of age
Non-clinical studies	1	Study 2 Definitive juvenile toxicity study to assess the toxic potential of ladarixin when administered daily by oral gavage to juvenile rats from post-natal day (PND) 10 to PND 45.

Area	Number of measures	Description
Clinical studies	3	Study 3 Randomized, double-blind and placebo-controlled study to assess pharmacokinetics (PK), efficacy and safety in children from 14 to less than 18 years of age (and adults) with new onset type 1 diabetes (LDX0319) Study 4 Randomized, double-blind and placebo-controlled study to assess the PK, efficacy and safety in children from 6 to less than 14 years of age with new onset type 1 diabetes Study 5 Randomized, double-blind and placebo-controlled study to assess the PK, efficacy and safety in children from 1 to less than 6 years of age with new onset type 1 diabetes
Extrapolation, modelling and simulation studies	2	Study 6 Physiologic Based Pharmacokinetic (PBPK) modelling and simulation study to support dose finding in the paediatric target population (2460250) Study 7 Population PK modelling and simulation study to support dose finding in the paediatric target population
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes